Kirsti Raiko
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kirsti Raiko has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Antonín Hlaváček
Institute of Analytical Chemistry of the Czech Academy of Sciences, Veveri 97, Brno 602 00, Czech Republic
1 shared publication - Hans H. Gorris
Department of Biochemistry, Faculty of Science, Masaryk University, Kamenice 5, 625 00 Brno, Czech Republic
1 shared publication - Iida Martiskainen
Department of Biotechnology, University of Turku, Turku, Finland
1 shared publication - Julian C. Brandmeier
Department of Biochemistry Faculty of Science Masaryk University Kamenice 5 Brno 625 00 Czech Republic
1 shared publication K E Juhani Airaksinen
Heart Center, Turku University Hospital and University of Turku , Turku , Finland
1 shared publication- Matthias Jürgen Mickert
Institute of Analytical Chemistry, Chemo- and Biosensors, University of Regensburg, Universitätsstraße 31, 93040, Regensburg, Germany
1 shared publication
Latest Publications
- Open Access
- 8 August 2026
- Published by Elsevier in Analytica Chimica Acta
- Vol. 1422
Combining sandwich and competitive immunoassay formats in a duplex lateral flow test for rapid iron-status assessment
- 8 August 2026
- Published by Elsevier in Analytica Chimica Acta
- Vol. 1422
Open AccessCombining sandwich and competitive immunoassay formats in a duplex lateral flow test for rapid iron-status assessment
- Open Access
- 18 June 2024
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 70 (8) , 1037-1045
Highly Sensitive Immunoassay for Long Forms of Cardiac Troponin T Using Upconversion Luminescence
Background: Long cardiac troponin T (cTnT) has been proposed to be a promising and more specific biomarker of acute myocardial infarction (AMI). As it represents a subfraction of circulating cTnT, detection of very low concentrations is a requirement. The aim of this study was to develop a novel, highly sensitive immunoassay for long cTnT. Methods: A two-step sandwich-type immunoassay for long cTnT was developed, utilizing upconverting nanoparticles (UCNPs) as reporters. The limits of detection and quantitation were determined for the assay. Linearity and matrix effects were evaluated. Performance with clinical samples was assessed with samples from patients with non-ST elevation myocardial infarction (NSTEMI, n = 30) and end-stage renal disease (ESRD, n = 37) and compared to a previously developed time-resolved fluorescence (TRF)-based long cTnT assay and a commercial high-sensitivity cTnT assay. Results: The novel assay reached a 28-fold lower limit of detection (0.40 ng/L) and 14-fold lower limit of quantitation (1.79 ng/L) than the previously developed TRF long cTnT assay. Li-heparin and EDTA plasma, but not serum, were found to be suitable sample matrixes for the assay. In a receiver operating characteristics curve analysis, the troponin ratio (long/total cTnT) determined with the novel assay showed excellent discrimination between NSTEMI and ESRD with an area under the curve of 0.986 (95% CI, 0.967–1.000). Conclusions: By utilizing upconversion luminescence technology, we developed a highly sensitive long cTnT assay. This novel assay can be a valuable tool for investigating the full potential of long cTnT as a biomarker for AMI. ClinicalTrials.gov Registration Number: NCT04465591
- 18 June 2024
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 70 (8) , 1037-1045
Open AccessHighly Sensitive Immunoassay for Long Forms of Cardiac Troponin T Using Upconversion Luminescence
Background: Long cardiac troponin T (cTnT) has been proposed to be a promising and more specific biomarker of acute myocardial infarction (AMI). As it represents a subfraction of circulating cTnT, detection of very low concentrations is a requirement. The aim of this study was to develop a novel, highly sensitive immunoassay for long cTnT. Methods: A two-step sandwich-type immunoassay for long cTnT was developed, utilizing upconverting nanoparticles (UCNPs) as reporters. The limits of detection and quantitation were determined for the assay. Linearity and matrix effects were evaluated. Performance with clinical samples was assessed with samples from patients with non-ST elevation myocardial infarction (NSTEMI, n = 30) and end-stage renal disease (ESRD, n = 37) and compared to a previously developed time-resolved fluorescence (TRF)-based long cTnT assay and a commercial high-sensitivity cTnT assay. Results: The novel assay reached a 28-fold lower limit of detection (0.40 ng/L) and 14-fold lower limit of quantitation (1.79 ng/L) than the previously developed TRF long cTnT assay. Li-heparin and EDTA plasma, but not serum, were found to be suitable sample matrixes for the assay. In a receiver operating characteristics curve analysis, the troponin ratio (long/total cTnT) determined with the novel assay showed excellent discrimination between NSTEMI and ESRD with an area under the curve of 0.986 (95% CI, 0.967–1.000). Conclusions: By utilizing upconversion luminescence technology, we developed a highly sensitive long cTnT assay. This novel assay can be a valuable tool for investigating the full potential of long cTnT as a biomarker for AMI. ClinicalTrials.gov Registration Number: NCT04465591
- Open Access
- 15 July 2021
- Published by Wiley in Advanced Healthcare Materials
- Vol. 10 (18) , 2100506
Effect of Particle Size and Surface Chemistry of Photon‐Upconversion Nanoparticles on Analog and Digital Immunoassays for Cardiac Troponin
Sensitive immunoassays are required for troponin, a low‐abundance cardiac biomarker in blood. In contrast to conventional (analog) assays that measure the integrated signal of thousands of molecules, digital assays are based on counting individual biomarker molecules. Photon‐upconversion nanoparticles (UCNP) are an excellent nanomaterial for labeling and detecting single biomarker molecules because their unique anti‐Stokes emission avoids optical interference, and single nanoparticles can be reliably distinguished from the background signal. Here, the effect of the surface architecture and size of UCNP labels on the performance of upconversion‐linked immunosorbent assays (ULISA) is critically assessed. The size, brightness, and surface architecture of UCNP labels are more important for measuring low troponin concentrations in human plasma than changing from an analog to a digital detection mode. Both detection modes result approximately in the same assay sensitivity, reaching a limit of detection (LOD) of 10 pg mL−1 in plasma, which is in the range of troponin concentrations found in the blood of healthy individuals.
- 15 July 2021
- Published by Wiley in Advanced Healthcare Materials
- Vol. 10 (18) , 2100506
Open AccessEffect of Particle Size and Surface Chemistry of Photon‐Upconversion Nanoparticles on Analog and Digital Immunoassays for Cardiac Troponin
Sensitive immunoassays are required for troponin, a low‐abundance cardiac biomarker in blood. In contrast to conventional (analog) assays that measure the integrated signal of thousands of molecules, digital assays are based on counting individual biomarker molecules. Photon‐upconversion nanoparticles (UCNP) are an excellent nanomaterial for labeling and detecting single biomarker molecules because their unique anti‐Stokes emission avoids optical interference, and single nanoparticles can be reliably distinguished from the background signal. Here, the effect of the surface architecture and size of UCNP labels on the performance of upconversion‐linked immunosorbent assays (ULISA) is critically assessed. The size, brightness, and surface architecture of UCNP labels are more important for measuring low troponin concentrations in human plasma than changing from an analog to a digital detection mode. Both detection modes result approximately in the same assay sensitivity, reaching a limit of detection (LOD) of 10 pg mL−1 in plasma, which is in the range of troponin concentrations found in the blood of healthy individuals.